Loading
Sionna Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$198M
No insider purchase over the last 90 days. The latest was filed 01 Jul 2025.
Sionna Therapeutics, Inc.: what insiders have been doing
Sionna Therapeutics, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Sionna Therapeutics, Inc. logged 42 filings by 10 insiders.
There is no open-market purchase to report; the filings show 28 sales worth €61.4M by 5 insiders. The largest single trade was a sale of €18.8M by RA Capital Management, L.P., published on 21 September 2026, equal to 9.1% of the market capitalisation.
Compared with its exchange (5,808 companies, median 19 filings), a count of 42 filings is above the norm. Our records for Sionna Therapeutics, Inc. go back to 2025, with 1 purchase and 39 sales on the open market in total. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -75.3 m USD.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
76
Thresholds
n/a
Buy Volume
€812,849
1 ops. · all time
Sell Volume
€66M
39 ops. · all time
Who traded when
BuySaleBooth Bruce17 sales
Orbimed Advisors LLC10 sales
Peter A. Thompson10 sales
RA Capital Management, L.P.5 sales
Elena Ridloff3 sales
Michael Cloonan2 sales
+2 other insiders
Since the insiders bought
- +110.8%Entry US$20.87 · Close at T+365 US$43.99
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Sionna Therapeutics, Inc. Hold (neutral), based on 7 analysts. Average price target: US$21.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.38
Analyst consensus
7 analystsHold
US$5.00Target US$21.00(+379%)US$63.00
Income statement
EBITDA-US$88.3M
Net income-US$75.3M0.0% margin
Valuation
PER (forward)-2.0x
P/Book0.7x
Balance sheet & cash
Market capUS$198M
Total debtUS$8.7M
Free Cash Flow-US$66.7M
Debt / Equity3%
Profitability & ownership
ROE-32.3%
ROA-21.5%
% insiders7.9%
% institutions99.2%
Last declaration on 21 September 2026
Declarations76 total
3,415,011 shares@ US$6.329.06% mcap96.0% of flowCommon StockSEC:0001231919-26-001201:0
33,800 shares@ US$7.460.11% mcap1.1% of flowCommon StockSEC:0001231919-26-001201:1
109,025 shares0Common StockSEC:0001704336-26-000005:0
47,269 shares0Common StockSEC:0001772518-26-000004:0
47,268 shares0Common StockSEC:0001772518-26-000004:1
109,025 shares0Common StockSEC:0001704336-26-000005:1
28,133 shares0Common StockSEC:0002061851-26-000009:0
28,132 shares0Common StockSEC:0002061851-26-000009:1
50,000 shares0Common StockSEC:0002046433-26-000005:0
50,000 shares0Common StockSEC:0002046433-26-000005:1
3,448,811 shares@ US$6.3319.17% mcap100.0% of flowCommon StockSEC144:0001315082-26-000002
85,918 shares@ US$44.861.62% mcap11.2% of flowCommon StockSEC:0000947871-26-000694:0
▼
Same trade as the filing by Orbimed Advisors LLC, counted once · View ↗
85,918 shares@ US$44.861.62% mcap11.2% of flowCommon StockSEC:0000947871-26-000695:0
10,250 shares@ US$6.110.026% mcap9.0% of flowCommon StockSEC:0002061851-26-000006:0
10,250 shares@ US$43.59630.19% mcap64.4% of flowCommon StockSEC:0002061851-26-000006:1
10,250 shares@ US$43.990.19% mcap100.0% of flowCommonSEC144:0001950047-26-006887
52,397 shares@ US$44.680.87% mcap6.6% of flowCommon StockSEC:0000947871-26-000458:0
2,948 shares@ US$44.520.049% mcap0.4% of flowCommon StockSEC:0000947871-26-000458:1
▼
Same trade as the filing by Orbimed Advisors LLC, counted once · View ↗
2,948 shares@ US$44.520.049% mcap0.4% of flowCommon StockSEC:0000947871-26-000459:1
▼
Same trade as the filing by Orbimed Advisors LLC, counted once · View ↗
52,397 shares@ US$44.680.87% mcap6.6% of flowCommon StockSEC:0000947871-26-000459:0
47,814 shares@ US$44.510.79% mcap6.0% of flowCommon StockSEC:0000947871-26-000446:0
235,863 shares@ US$44.643.90% mcap29.8% of flowCommon StockSEC:0000947871-26-000446:1
226,906 shares@ US$45.343.82% mcap29.2% of flowCommon StockSEC:0000947871-26-000446:2
▼
Same trade as the filing by Orbimed Advisors LLC, counted once · View ↗
47,814 shares@ US$44.510.79% mcap6.0% of flowCommon StockSEC:0000947871-26-000447:0
▼
Same trade as the filing by Orbimed Advisors LLC, counted once · View ↗
235,863 shares@ US$44.643.90% mcap29.8% of flowCommon StockSEC:0000947871-26-000447:1
25 of 76 declarations
About Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a company focused on developing innovative therapies for the treatment of neurological diseases. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
